Week of the 23rd November
-
C4X Discovery, a British drug exploration company, has announced a license deal signed with Astra-Zeneca to develop an oral therapy for inflammatory and respiratory diseases. They’ll receive $2 million initially, with pre-clinical milestones of up to $16 million, with the potential of up to $420 million with clinical and commercial milestones, as well as royalties through commercialisation. The drug is part of the company’s NRF2 Activator programme, utilising the antioxidant making powerhouses to combat the inflammation associated with many respiratory diseases
-
The team behind Apple’s Face ID is developing tiny robots to deliver drugs into the brain, controlled by magnetic propulsion, to target hard to treat diseases. Trials have commenced delivering drugs to treat brain tumour and rare paediatric neurological disorder, where the robots will be used to poke a hole in a cyst. There are so many places in the body where science today cannot reach easily, and it hopes to address trickier, more common diseases such as Parkinson’s, Huntington’s, Alzheimer’s and strokes.
-
The United States healthcare facilities management market is anticipated to grow at a significant rate during the forecast period, 2023-2027, according to a recent report from Research and Markets. The market growth can be attributed to the increasing prevalence of chronic disorders and rising healthcare expenditure. In UK news One hundred thousand nursing staff are set to go on strike next month, the Royal College of Nursing has confirmed.
Week of the 30th November
-
Unh hosted an annual investor event on 29/11/22 in NYC and shares edged lower Tuesday as the forecast for 2023 was softer than what street estimated it to be . UNH said adjusted profits for the coming year, which begins in January, will likely range between $24.40-24.90$ per share, just shy of refinitiv forecasts of 24.9 per share, with overall revenues in region of $357 billion to 360 billion. There is now a blend of possibly a little bit of covid effect in the system, but cost of living affects, things like inflation, things like capacity constraints as the labour market tightness has affected different parts of system at different moments. Said ceo andrew witty. Stock went down approx 5 percent on that day
-
Neuralink is now confident that the device is ready for humans, and is working through the FDA approval process. The company said it was working to address concerns from the FDA regarding overheating of the device and also toxic chemicals seeping into the brain from the implant. The company wants to be able to help restore vision and enable people with severe disabilities to move and communicate by decoding brain activity. Clinical testing that proves an implantable device is safe and effective long-term would be necessary before a brain-computer interface, like Neuralink’s, could be widely rolled out to patients, neurotechnology experts said.
-
The Worldwide Healthcare Equipment Leasing Industry is Expected to Reach $71.6 Billion by 2027. This is mainly driven by rising chronic diseases with a growing patient population, increased number of diagnostic and surgical procedures, , rapid advancements in healthcare, and an increasing number of hospitals & diagnostic centres. However, the growing demand for refurbished equipment, the risk of healthcare equipment obsolescence, and the availability of multiple procuring options might hinder the growth of the global market.